{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:49:55Z","timestamp":1761061795928,"version":"3.37.3"},"reference-count":26,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100010849","name":"Health and Family Planning Commission of Wuhan Municipality","doi-asserted-by":"crossref","award":["Grant NO.WX19B04"],"award-info":[{"award-number":["Grant NO.WX19B04"]}],"id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nature Science Foundation of Hubei Province, China","award":["Grant No. WJ2019H427"],"award-info":[{"award-number":["Grant No. WJ2019H427"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>It has been observed previously that chronic methamphetamine\n(METH) administration could upregulate neuropeptide Y (NPY) expression and promote\natherosclerotic formation in apolipoprotein E knockout (ApoE-\/-) mice fed with a normal\ncholesterol or high diet and NPY might be involved in the pathogenesis of METHinduced\natherogenic effects through NPY Y1 receptor pathway. Vulnerable coronary\natherosclerotic plaque (VP) is a critical pathological finding responsible for the acute\ncoronary syndrome (ACS). In this study, we explored whether METH abuse could\naggravate the formation of VP in ApoE-\/- mice fed with high cholesterol diet.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this study was to observe if chronic METH administration\ncould aggravate vulnerable plaque (VP) formation in ApoE-\/- mice fed with a highcholesterol\ndiet<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Male ApoE-\/- mice fed with a high-cholesterol diet were intraperitoneally\ninjected with normal saline (NS) or 8 mg\/kg\/day METH (M8) for 24 weeks. Body weight\nwas monitored from baseline to 24 weeks at 2 weeks intervals. After 24 weeks of\ntreatment, plasma lipid variables were measured. Movat's staining and immunohistochemical\nstaining were performed on frozen sections of the aortic roots to calculate\nVP percentage and intraplaque hemorrhage (IPH) percentage and detect expression of\nNPY, vascular endothelial growth factor (VEGF), and CD31. In vitro, the expressions of\nY2R, VEGF, and CD31 were detected by immunofluorescence staining in aortic\nendothelial cells incubated with PBS, 100\u03bcM METH, 10nmol NPY, or 100\u03bcM METH plus\n10nmol NPY for 12 hours.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The CD31 positive area, percentage of IPH, VP, and the expressions of NPY\nand VEGF were significantly increased in the M8 group than in the NS group. In vitro,\nthe expressions of Y2R, VEGF, and CD31 were significantly increased in the\nMETH+NPY group than in the PBS, METH, and NPY groups and these effects could be\nblunted by treatment with a Y2R antagonist or DPPIV inhibitor.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Chronic METH administration could aggravate VP in ApoE-\/- mice fed with\na high-cholesterol diet, possibly through upregulating vascular NPY and VEGF\nexpression and promoting angiogenesis and vessel rupture in atherosclerotic plaques.\nOur findings indicated that increased VP formation might contribute to the development\nof acute coronary syndrome post-chronic METH abuse by activating DPPIV\/NPY\/Y2R\npathway.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524023666230321095233","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:07:51Z","timestamp":1679458071000},"page":"495-504","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Administration of Methamphetamine Aggravates\nAtherosclerotic Vulnerable Plaques in Apolipoprotein E Knockout\nMice Fed with a High-cholesterol Diet"],"prefix":"10.2174","volume":"24","author":[{"given":"Xiaoxue","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital; Puai Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital; Puai Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital; Puai Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital; Puai Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-7854","authenticated-orcid":true,"given":"Liqun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital; Puai Hospital, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.2008.02231.x","volume":"103","author":"Kaye S.","year":"2008","unstructured":"Kaye S.; Darke S.; Duflou J.; McKetin R.; Methamphetamine-related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Addiction  2008,103(8),1353-1360","journal-title":"Addiction"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0736-4679(03)00031-3","volume":"24","author":"Turnipseed S.D.","year":"2003","unstructured":"Turnipseed S.D.; Richards J.R.; Kirk J.D.; Diercks D.B.; Amsterdam E.A.; Frequency of acute coronary syndrome in patients presenting to the Emergency Department with chest pain after methamphetamine use. J Emerg Med  2003,24(4),369-373","journal-title":"J Emerg Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.atherosclerosis.2015.09.001","volume":"243","author":"Gao B.","year":"2015","unstructured":"Gao B.; Li L.; Zhu P.; Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE\u2212\/\u2212 knockout mice fed normal diet. Atherosclerosis  2015,243(1),268-277","journal-title":"Atherosclerosis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"55064","DOI":"10.18632\/oncotarget.19020","volume":"8","author":"Zhu P.","year":"2017","unstructured":"Zhu P.; Li L.; Gao B.; Impact of chronic methamphetamine treatment on the atherosclerosis formation in ApoE\u2212\/\u2212 mice fed a high cholesterol diet. Oncotarget  2017,8(33),55064-55072","journal-title":"Oncotarget"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/jnc.12052","volume":"123","author":"Gon\u00e7alves J.","year":"2012","unstructured":"Gon\u00e7alves J.; Baptista S.; Olesen M.V.; Methamphetamine-induced changes in the mice hippocampal neuropeptide Y system: implications for memory impairment. J Neurochem  2012,123(6),1041-1053","journal-title":"J Neurochem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2014.04.025","volume":"235","author":"Lagraauw H.M.","year":"2014","unstructured":"Lagraauw H.M.; Westra M.M.; Bot M.; Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. Atherosclerosis  2014,235(1),196-203","journal-title":"Atherosclerosis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12265-011-9271-5","volume":"4","author":"Li L.","year":"2011","unstructured":"Li L.; Najafi A.H.; Kitlinska J.B.; Of mice and men: Neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. J Cardiovasc Transl Res  2011,4(3),351-362","journal-title":"J Cardiovasc Transl Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10571-011-9793-z","volume":"32","author":"Hirsch D.","year":"2012","unstructured":"Hirsch D.; Zukowska Z.; NPY and stress 30 years later: The peripheral view. Cell Mol Neurobiol  2012,32(5),645-659","journal-title":"Cell Mol Neurobiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/sj.npp.1300247","volume":"28","author":"Segal D.S.","year":"2003","unstructured":"Segal D.S.; Kuczenski R.; O\u2019Neil M.L.; Melega W.P.; Cho A.K.; Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology  2003,28(10),1730-1740","journal-title":"Neuropsychopharmacology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"dmm.009977","DOI":"10.1242\/dmm.009977","volume":"6","author":"Najafi AH","year":"2013","unstructured":"Najafi AH; Aghili N; Tilan JU; A new murine model of stress-induced complex atherosclerotic lesions. Dis Model Mech  2013,6(2),dmm.009977","journal-title":"Dis Model Mech"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e006775","DOI":"10.1161\/JAHA.117.006775","volume":"6","author":"Vendrov A.E.","year":"2017","unstructured":"Vendrov A.E.; Stevenson M.D.; Alahari S.; Attenuated superoxide dismutase 2 activity induces atherosclerotic plaque instability during aging in hyperlipidemic mice. J Am Heart Assoc  2017,6(11),e006775","journal-title":"J Am Heart Assoc"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"118478","DOI":"10.1016\/j.lfs.2020.118478","volume":"262","author":"Chen F.","year":"2020","unstructured":"Chen F.; Zhou Y.; Yang K.; Shen M.; Wang Y.; NPY stimulates cholesterol synthesis acutely by activating the SREBP2-HMGCR pathway through the Y1 and Y5 receptors in murine hepatocytes. Life Sci  2020,262,118478","journal-title":"Life Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijcard.2016.06.138","volume":"220","author":"Zhu P.","year":"2016","unstructured":"Zhu P.; Sun W.; Zhang C.; Song Z.; Lin S.; The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. Int J Cardiol  2016,220,235-241","journal-title":"Int J Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2337\/db11-1142","volume":"61","author":"Bruinstroop E.","year":"2012","unstructured":"Bruinstroop E.; Pei L.; Ackermans M.T.; Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes  2012,61(5),1043-1050","journal-title":"Diabetes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"793755","DOI":"10.3389\/fcvm.2022.793755","volume":"9","author":"Della-Morte D.","year":"2022","unstructured":"Della-Morte D.; Dong C.; Crisby M.; Association of carotid plaque morphology and glycemic and lipid parameters in the northern manhattan study. Front Cardiovasc Med  2022,9,793755","journal-title":"Front Cardiovasc Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.6061\/clinics\/2016(04)11","volume":"71","author":"Fonseca F.A.H.","year":"2016","unstructured":"Fonseca F.A.H.; de Oliveira Izar M.C.; High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics  2016,71(4),235-242","journal-title":"Clinics"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3389\/fphys.2018.01718","volume":"9","author":"Hu S.","year":"2018","unstructured":"Hu S.; Liu Y.; You T.; Zhu L.; Semaphorin 7A promotes VEGFA\/VEGFR2-mediated angiogenesis and intraplaque neovascularization in ApoE-\/- mice. Front Physiol  2018,9,1718","journal-title":"Front Physiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI16929","volume":"111","author":"Lee E.W.","year":"2003","unstructured":"Lee E.W.; Michalkiewicz M.; Kitlinska J.; Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest  2003,111(12),1853-1862","journal-title":"J Clin Invest"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.toxlet.2020.09.013","volume":"334","author":"Ventura F.","year":"2020","unstructured":"Ventura F.; Muga M.; Coelho-Santos V.; Fontes-Ribeiro C.A.; Leit\u00e3o R.A.; Silva A.P.; Protective effect of neuropeptide Y2 receptor activation against methamphetamine-induced brain endothelial cell alterations. Toxicol Lett  2020,334,53-59","journal-title":"Toxicol Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1096\/fj.05-4770fje","volume":"20","author":"Movafagh S.","year":"2006","unstructured":"Movafagh S.; Hobson J.P.; Spiegel S.; Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J  2006,20(11),1924-1926","journal-title":"FASEB J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1056\/NEJMoa035655","volume":"349","author":"Kolodgie F.D.","year":"2003","unstructured":"Kolodgie F.D.; Gold H.K.; Burke A.P.; Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med  2003,349(24),2316-2325","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.ATV.0000178991.71605.18","volume":"25","author":"Virmani R.","year":"2005","unstructured":"Virmani R.; Kolodgie F.D.; Burke A.P.; Atherosclerotic plaque progression and vulnerability to rupture: Agiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol  2005,25(10),2054-2061","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/apha.12438","volume":"213","author":"Chistiakov D.A.","year":"2015","unstructured":"Chistiakov D.A.; Orekhov A.N.; Bobryshev Y.V.; Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol  2015,213(3),539-553","journal-title":"Acta Physiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2017.04.028","volume":"816","author":"Parma L.","year":"2017","unstructured":"Parma L.; Baganha F.; Quax P.H.A.; de Vries M.R.; Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur J Pharmacol  2017,816,107-115","journal-title":"Eur J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/ATVBAHA.106.137851","volume":"27","author":"Michel J.B.","year":"2007","unstructured":"Michel J.B.; Thaunat O.; Houard X.; Meilhac O.; Caligiuri G.; Nicoletti A.; Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol  2007,27(6),1259-1268","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.atherosclerosis.2014.03.020","volume":"234","author":"Michel J.B.","year":"2014","unstructured":"Michel J.B.; Martin-Ventura J.L.; Nicoletti A.; Ho-Tin-No\u00e9 B.; Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis  2014,234(2),311-319","journal-title":"Atherosclerosis"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230321095233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214801\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230321095233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:10:44Z","timestamp":1713939044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214801\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524023666230321095233","relation":{},"ISSN":["1566-5240"],"issn-type":[{"type":"print","value":"1566-5240"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}